Article Text

Download PDFPDF
Glial fibrillary acidic protein IgG related myelitis: characterisation and comparison with aquaporin-4-IgG myelitis

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors ES: analysis and interpretation of data, drafting of the manuscript and figures. PPM, AM, SJP, SRH, BGW, AJA, KNK, TJK, EAJ, NLZ, AZ, DMW, JJ: acquisition of data, analysis and interpretation of data, critical revision of the manuscript for intellectual content. EPF: study concept and design, acquisition of data, analysis and interpretation of data, study supervision.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interest AM and SRH are named inventors on a patent application filed by Mayo Foundation relating to GFAP antibody. AM consulted for Grifols, Medimmune and Euroimmun and received research support from MedImmune and Euroimmun. SJP has a financial interest in patents (12/678,350 filed 2010 and 12/573,942 filed 2008) that relate to functional AQP4/neuromyelitis optica-IgG assays and neuromyelitis optica-IgG as a cancer marker. SJP has provided consultation to Alexion Pharmaceuticals, Medimmune and Chugai Pharma USA but has received no personal fees or personal compensation for these consulting activities. All compensation for consulting activities is paid directly to Mayo Clinic. SJP has received a research grant from Alexion Pharmaceuticals for an investigator-initiated study and support from the NIH(RO1 NS065829-01) and the Guthy Jackson Charitable Foundation for neuromyelitisoptica research. BGW receives royalties from RSR Ltd, Oxford University, Hospices Civil de Lyon and MVZ Labor PD Dr. Volkmann und Kollegen GbR for a patent of NMO-IgG as a diagnostic test for NMO and related disorders. He serves as a member of an adjudication committee for clinical trials in NMO being conducted by MedImmune and Alexion pharmaceutical companies. He is aconsultant for Caladrius Biosciences regarding a clinical trial for NMO.

  • Patient consent Not required.

  • Ethical approval Mayo Clinic Institutional Review Board.

  • Provenance and peer review Not commissioned; externally peer reviewed.